Last reviewed · How we verify

NCT04594824: COIN

Defining Reference Ranges for Cerebral Oxygenation In Neonates (COIN) During Immediate Neonatal Transition After Birth

Completed Last updated 31 May 2023
What this trial tests

trial testing No Intervention in Neonatal Adaptation in 192 participants. Completed in 4 April 2022.

Timeline
13 November 2020
Primary endpoint
4 April 2022
4 April 2022

Quick facts

Lead sponsorMedical University of Graz
StatusCompleted
Study typeOBSERVATIONAL
Enrollment192
Start date13 November 2020
Primary completion4 April 2022
Estimated completion4 April 2022
Sites1 location across Austria

Drugs / interventions tested

Conditions studied

Sponsor

Medical University of Graz

Who can join

Adults 0 Minutes to 15 Minutes, any sex, with Neonatal Adaptation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Especially in neonates non-invasive methods are required for monitoring the complex changes during immediate transition after birth to improve assessment of neonate and eventually resuscitation. During this period especially, the brain is vulnerable and monitoring the brain and possible influencing factors of cerebral oxygenation and perfusion are of great interest. To initiate and guide therapies based on cerebral oxygenation, it is important to define reference ranges.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of No Intervention

Trials testing the same drug.

Other recruiting trials for Neonatal Adaptation

Currently open trials in the same condition.

Other Medical University of Graz trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04594824.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing